Intellia Therapeutics, Inc. has announced an amendment to its Open Market Sale Agreement with Jefferies LLC. The amendment, dated March 2, 2026, brings significant changes to the agreement originally dated March 4, 2022, and previously amended on February 23, 2024.
The first notable change is the increase in the reference amount in the preamble on page 1 of the Sales Agreement. The original amount of "$750,000,000" has now been amended to "$1,035,316,650."
Additionally, the Issuance Notice attached as Exhibit A to the Sales Agreement has been updated to include the date "March 2, 2026," in addition to the previous dates of "March 4, 2022," and "February 23, 2024."
Further amendments include a change in the contact person listed in Schedule A of the Sales Agreement from "Glen Goddard ([email protected])" to "Edward Dulac ([email protected])."
The Company has committed to filing a Prospectus Supplement pursuant to Rule 424(b) of the Securities Act of 1933, reflecting this Amendment within two Business Days of the date of the amendment.
The amendment is stated to be effective as of March 2, 2026, and it is incorporated into and forms a part of the Sales Agreement.
The amendment includes standard provisions regarding execution in counterparts and the governing law, with both parties consenting to the application of New York civil law.
Finally, the amendment clarifies that, except for the changes outlined, the Sales Agreement shall remain in full force and effect.
The amendment was duly executed by John M. Leonard, Chief Executive Officer and President of Intellia Therapeutics, Inc., and Michael Magarro, Managing Director of Jefferies LLC. The market has reacted to these announcements by moving the company's shares 5.31% to a price of $12.50. For more information, read the company's full 8-K submission here.
